| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ana Filipa Martins, Mónica Santos, Francisco Rosári. Caloric restriction as a possible pitfall for persistent acromegaly follow-up - case report. BMC endocrine disorders. vol 23. issue 1. 2023-03-27. PMID:36973824. |
acromegaly diagnosis is established when plasma levels of igf-1 are increased and the oral glucose tolerance test (ogtt) with 75gr of glucose can't suppress growth hormone (gh) levels. |
2023-03-27 |
2023-08-14 |
Not clear |
| Anamil Khiyami, Neha Mehrotra, Sharini Venugopal, Hussain Mahmud, Georgios A Zenonos, Paul A Gardner, Pouneh K Fazel. IGF-1 is positively associated with BMI in patients with acromegaly. Pituitary. 2023-03-17. PMID:36930352. |
acromegaly is a disorder characterized by igf-1 excess due to autonomous gh secretion. |
2023-03-17 |
2023-08-14 |
Not clear |
| Anamil Khiyami, Neha Mehrotra, Sharini Venugopal, Hussain Mahmud, Georgios A Zenonos, Paul A Gardner, Pouneh K Fazel. IGF-1 is positively associated with BMI in patients with acromegaly. Pituitary. 2023-03-17. PMID:36930352. |
in individuals without acromegaly, igf-1 is not only influenced by gh secretion but is also sensitive to other factors including nutritional status, as evidenced by the inverted u-shaped association between bmi and igf-1; in low-weight individuals (bmi < 18.5 kg/m |
2023-03-17 |
2023-08-14 |
Not clear |
| Maria João Bugalho, Mariana Lopes-Pinto, Carlos Lemos, Ema Nobr. In Search of the Hyperglycemic Threshold Required to Induce Growth Hormone (GH) Suppression. Cureus. vol 15. issue 1. 2023-03-06. PMID:36874742. |
introduction according to the 2014 endocrine society clinical practice guideline on acromegaly, the confirmation of acromegaly diagnosis is established by finding a lack of suppression of growth hormone (gh) to < 1 ug/l following documented hyperglycemia during an oral glucose tolerance test. |
2023-03-06 |
2023-08-14 |
Not clear |
| Sher Bahadur Poudel, Ryan R Ruff, Gozde Yildirim, Manisha Dixit, Benoit Michot, Jennifer L Gibbs, Silvana Duran Ortiz, John J Kopchick, Thorsten Kirsch, Shoshana Yaka. Excess growth hormone triggers inflammation-associated arthropathy, subchondral bone loss, and arthralgia. The American journal of pathology. 2023-03-04. PMID:36870529. |
in humans, excess gh secretion due to pituitary adenoma, seen in patients with acromegaly, results in severe arthropathies. |
2023-03-04 |
2023-08-14 |
mouse |
| Cesar Luiz Boguszewski, Margaret Cristina da Silva Boguszewski, Wouter W de Herde. The science behind the relations among cancer, height, growth patterns and growth hormone axis. Endocrine-related cancer. 2023-02-13. PMID:36779772. |
in animal and human models, genetic defects associated with gh deficiency or resistance are associated with protection from tumor development, while risk of malignancies in acromegaly or in patients exposed to recombinant gh therapy has long been a matter of concern and scrutiny. |
2023-02-13 |
2023-08-14 |
human |
| Daniel G Henriques, Renan Lyra Miranda, Rômulo Sperduto Dezonne, Luiz Eduardo Wildemberg, Aline Helen da Silva Camacho, Leila Chimelli, Leandro Kasuki, Elisa B Lamback, Alexandro Guterres, Monica R Gadelh. miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. International journal of molecular sciences. vol 24. issue 3. 2023-02-11. PMID:36769196. |
acromegaly is a chronic systemic disease caused in the vast majority of cases by growth hormone (gh)-secreting adenoma, with surgery being the first-line treatment. |
2023-02-11 |
2023-08-14 |
Not clear |
| Shouan Zhu, Huanhuan Liu, Trent Davis, Craig R G Willis, Reetobrata Basu, Luke Witzigreuter, Stephen Bell, Nathaniel Szewczyk, Martin K Lotz, Marcheta Hill, Roberto J Fajardo, Patrick M O'Connor, Darlene E Berryman, John J Kopchic. Excessive growth hormone promotes joint degeneration and chondrocyte metabolic dysfunction in mice. Arthritis & rheumatology (Hoboken, N.J.). 2023-02-10. PMID:36762426. |
many patients with acromegaly, a hormonal disorder with excessive growth hormone (gh), report pain in joints. |
2023-02-10 |
2023-08-14 |
mouse |
| Rajesh Chhabra, Ashwani Kumar, R S Virk, Pinaki Dutta, Chirag Ahuja, Manju Mohanty, Sivashanmugam Dhandapan. Outcomes in pituitary adenoma causing acromegaly following endoscopic endonasal transsphenoidal surgery. Journal of neurosciences in rural practice. vol 13. issue 4. 2023-02-06. PMID:36743751. |
the objectives of the study were to study the analysis of outcomes after endoscopic endonasal transsphenoidal surgery (eetss) in acromegaly in terms of surgical complications, clinical improvement, endocrinological remission, achievement of prognostically critical growth hormone (gh) level, and requirement of additional treatment. |
2023-02-06 |
2023-08-14 |
Not clear |
| Madisyn Oxley, Heather Francis, Keisaku Sat. Growth hormone signaling in liver diseases: Therapeutic potentials and controversies. Seminars in liver disease. 2023-01-18. PMID:36652958. |
gh deficiency causes short stature or dwarfism, and excess gh causes acromegaly. |
2023-01-18 |
2023-08-14 |
Not clear |
| Ruixin Cao, Di Zhang, Haichang Xing, Mingyan Wang, Zhongshuo Lu, Bing Fa. Acromegaly with joint pain as an initial symptom: A case report. International journal of rheumatic diseases. 2023-01-17. PMID:36647758. |
acromegaly is caused by the long-term excessive secretion of growth hormone (gh) and insulin-like growth factor-1 (igf-1). |
2023-01-17 |
2023-08-14 |
Not clear |
| Artak Labadzhyan, Shlomo Melme. Molecular targets in acromegaly. Frontiers in endocrinology. vol 13. 2022-12-22. PMID:36545335. |
currently available medical therapies for patients with acromegaly bind to somatostatin receptors, gh receptor, or dopamine receptors, and lead to attainment of disease control in most patients. |
2022-12-22 |
2023-08-14 |
Not clear |
| Shilpa Gurnurkar, Unnati Patel, Jennifer Seekford, Mauri Carakushansky, Madhuradhar Chegond. Two Unusual Cases of Pituitary Tumors Presenting with Pediatric Acromegaly. Cureus. vol 14. issue 11. 2022-12-21. PMID:36540490. |
gigantism and acromegaly are most commonly caused by a growth hormone (gh)-secreting pituitary adenoma. |
2022-12-21 |
2023-08-14 |
Not clear |
| Zhengxing Xie, Yan Zhuang, Zongqiang Zhang, Jieping Li. Presence of cerebral microbleeds is associated with cognitive decline in acromegaly. Frontiers in oncology. vol 12. 2022-12-12. PMID:36505847. |
this study is designed to investigate the prevalence and the radiographic patterns of cmbs and the association between cognitive function and acromegaly-related cmbs in growth hormone (gh)-secreting pituitary adenoma, which is characterized by acromegaly. |
2022-12-12 |
2023-08-14 |
Not clear |
| Ryutaro Makino, Shingo Fujio, Tomoko Hanada, Masanori Yonenaga, Shigeru Kawade, Hiroshi Hashiguchi, Yoshihiko Nishio, Nayuta Higa, Kazunori Arita, Koji Yoshimoto, Ryosuke Hanay. Delayed postoperative hyponatremia in patients with acromegaly: incidence and predictive factors. Pituitary. 2022-11-03. PMID:36323977. |
growth hormone (gh) enhances renal sodium reabsorption; however, the association between postoperative gh reduction and dph in acromegaly is unclear. |
2022-11-03 |
2023-08-14 |
Not clear |
| Xia Zhang, Jin Ma, Lüe Li, Linyang Gan, Huijing He, Enhua Shao, Xiaopeng Guo, Huijuan Zhu, Hui You, Yong Zhong, Bing Xin. Elevated IGF-1 and GH Levels Are Correlated With a Thicker Iris and Wider Anterior Chamber Angle in Treatment-Naïve Acromegaly Patients. Investigative ophthalmology & visual science. vol 63. issue 11. 2022-10-28. PMID:36306142. |
elevated igf-1 and gh levels are correlated with a thicker iris and wider anterior chamber angle in treatment-naïve acromegaly patients. |
2022-10-28 |
2023-08-14 |
Not clear |
| Xia Zhang, Jin Ma, Lüe Li, Linyang Gan, Huijing He, Enhua Shao, Xiaopeng Guo, Huijuan Zhu, Hui You, Yong Zhong, Bing Xin. Elevated IGF-1 and GH Levels Are Correlated With a Thicker Iris and Wider Anterior Chamber Angle in Treatment-Naïve Acromegaly Patients. Investigative ophthalmology & visual science. vol 63. issue 11. 2022-10-28. PMID:36306142. |
to compare the difference in anterior segment biometrics derived from anterior segment optical coherence tomography (as-oct) between treatment-naïve acromegaly patients and normal controls and evaluate the correlations between above biometrics and insulin-like growth factor 1 (igf-1) and growth hormone (gh) levels. |
2022-10-28 |
2023-08-14 |
Not clear |
| Ivana Ságová, Daniela Kantárová, Marián Mokáň, Peter Vaňug. Changes in Cross-Sectional Area of the Median Nerve and Body Composition Parameters after Treatment of Acromegaly: 1 year Follow-Up. International journal of endocrinology. vol 2022. 2022-10-24. PMID:36277124. |
changes in levels of growth hormone (gh) and insulin-like growth factor i (igf-i) and body composition are potential parameters in pathology of median neuropathy in acromegaly. |
2022-10-24 |
2023-08-14 |
Not clear |
| Suneela S Dhaneshwar, Shrishti Shandily, Vatsaly. Growth Hormone Excess: Implications and Management. Endocrine, metabolic & immune disorders drug targets. 2022-10-14. PMID:36237164. |
acromegaly is described by oversecretion of growth hormone (gh) and, subsequently, insulin-like growth factor 1 (igf-1), ascribed in most cases to a pituitary adenoma. |
2022-10-14 |
2023-08-14 |
human |
| Ummu Mutlu, Ozge Telci Caklili, Mehmet Barburoglu, Sema Yarma. Frequency of hyperostosis frontalis interna in patients with active acromegaly: is there a possible role of GH excess or hyperprolactinemia in its etiopathogenesis? Hormones (Athens, Greece). 2022-10-12. PMID:36223065. |
frequency of hyperostosis frontalis interna in patients with active acromegaly: is there a possible role of gh excess or hyperprolactinemia in its etiopathogenesis? |
2022-10-12 |
2023-08-14 |
Not clear |